# Plain Language Summary: Facilitating Innovative Nuclear Diagnostics Act of 2023

This bill changes how Medicare pays for certain diagnostic imaging drugs used in nuclear medicine scans. Right now, these specialized drugs are bundled into the overall hospital payment for an outpatient procedure, meaning hospitals absorb the full cost regardless of how expensive the drug actually is. This bill says that starting in 2024, when a diagnostic nuclear medicine drug costs $500 or more per day, Medicare should pay for that drug separately instead of lumping it into the general procedure payment.

Here's why this matters in practical terms: Imagine a patient needs a PET scan or other nuclear imaging test to detect cancer. The hospital uses an expensive diagnostic radiopharmaceutical (a radioactive drug injected into the patient's body to light up problem areas). Under current rules, the hospital gets one flat payment for the whole procedure, and if that drug is very expensive, the hospital loses money on that patient's care. This can discourage hospitals from offering these newer, more advanced diagnostic tools. By paying separately for expensive drugs, Medicare ensures hospitals can afford to keep these diagnostic options available to patients who need them.

The bill includes a safeguard to prevent Medicare costs from skyrocketing: the total amount Medicare spends overall must stay the same. If separate payments for expensive drugs go up, Medicare will adjust other payments downward to balance it out. Additionally, patients' out-of-pocket costs won't change—they'll still pay the same copayment they would have paid before. The threshold of $500 will increase each year along with other Medicare payment adjustments, so it stays relevant as drug costs change over time.

Facilitating Innovative Nuclear Diagnostics Act of 2023

Dunn, Neal P.

Facilitating Innovative Nuclear Diagnostics Act of 2023 This bill establishes separate payment requirements for diagnostic radiopharmaceuticals under the Medicare prospective payment system for hospital outpatient department services. The bill's requirements apply to diagnostic radiopharmaceuticals that have an average daily cost of $500 or more in 2024 and as adjusted based on a specified fee schedule factor in each year thereafter.